{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:09:12Z","timestamp":1793257752790,"version":"4.5.0"},"reference-count":83,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,5,13]]},"abstract":"<jats:sec id=\"ab-jrv250002-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100\u202f000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150\u202f000 people in the US and 5 million worldwide have CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250002-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, which is defined by the\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      oncogene that develops after fusion of the\n                      <jats:italic>ABL1<\/jats:italic>\n                      proto-oncogene to the constitutively active\n                      <jats:italic>BCR<\/jats:italic>\n                      gene. Approximately 90% of people with CML present with an indolent chronic phase of CML, defined as blasts of less than 10% in the blood or bone marrow, absence of extramedullary evidence of leukemia, basophils of less than 20%, and platelet counts of 100 to 1000 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L. The most advanced stage is CML blastic phase (CML-BP), characterized by the World Health Organization as 20% or more blasts\/immature cells and by the MD Anderson Cancer Center and European LeukemiaNet as 30% or more. Approximately 1% to 2% of patients with CML present with CML-BP. Since 2000, first-generation tyrosine kinase inhibitors (TKIs) targeting\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      , such as imatinib, and second-generation TKIs, such as bosutinib, dasatinib, and nilotinib, have improved CML-related mortality from 10% to 20% per year to 1% to 2% per year, such that patients with CML have survival rates similar to those of a general age-matched population. Six\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      TKIs have been approved by the US Food and Drug Administration, including 5 that are first-line treatment (imatinib, dasatinib, bosutinib, nilotinib, and asciminib) and 5 approved for treatment after disease progression despite initial therapy (dasatinib, bosutinib, nilotinib, ponatinib, asciminib). Effects on improved survival are similar with all TKIs, although more patients are able to promptly achieve and maintain\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      clearance with second- and third-generation TKIs. Medication adherence is important to maintain treatment responsiveness. All TKIs are associated with hematologic toxicity, such as myelosuppression, with additional agent-specific adverse effects, such as pleural effusion (dasatinib), arterio-occlusive events such as myocardial infarction, stroke, and peripheral artery disease (nilotinib, ponatinib), gastrointestinal disturbance (bosutinib), or increased amylase and lipase with pancreatitis (ponatinib, asciminib, nilotinib). These adverse effects should be considered when selecting a TKI. Allogeneic hematopoietic stem cell transplant is a reasonably safe therapy, with cure rates ranging from 20% to 60% based on the stage of CML at the time of transplant. Stem cell transplant is reserved for patients with CML who do not respond to second-generation TKIs, those with intolerance to multiple TKIs, or those with accelerated-phase CML or CML-BP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250002-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia is a myeloproliferative neoplasm that can typically be effectively treated with TKIs, improving survival similar to that of a general age-matched population. Many patients require continuous TKI therapy. Therefore, TKI therapy should be selected with consideration of adverse effects, and patients should be helped to maximize adherence to TKI treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.0220","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:31:56Z","timestamp":1742211116000},"page":"1618","source":"Crossref","is-referenced-by-count":118,"title":["Chronic Myeloid Leukemia"],"prefix":"10.1001","volume":"333","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"jrv250002r1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"23","key":"jrv250002r4","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy\u2014the Surveillance, Epidemiology, and End Results database, 2000-2019.","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"issue":"12","key":"jrv250002r5","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"jrv250002r6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/10428199309047865","article-title":"Animal models of BCR\/ABL-induced leukemias.","volume":"11","author":"Daley","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"jrv250002r7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"jrv250002r8","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2014-10-567784","article-title":"The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.","volume":"125","author":"Barrett","year":"2015","journal-title":"Blood"},{"issue":"11","key":"jrv250002r9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250002r10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"jrv250002r11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia.","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv250002r12","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML Study IV and impact of non-CML determinants.","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"jrv250002r13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023\u2014common ground and common sense.","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"jrv250002r14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"jrv250002r15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"jrv250002r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"jrv250002r17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/hematology.2019000050","article-title":"Meeting the needs of CML patients in resource-poor countries.","volume":"2019","author":"Malhotra","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"jrv250002r18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"10","key":"jrv250002r19","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"jrv250002r20","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"issue":"1","key":"jrv250002r21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"5","key":"jrv250002r22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jmoldx.2013.04.007","article-title":"BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.","volume":"15","author":"Press","year":"2013","journal-title":"J Mol Diagn"},{"issue":"7","key":"jrv250002r23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-022-00696-4","article-title":"Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases.","volume":"12","author":"Abdelmagid","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"jrv250002r24","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"issue":"5","key":"jrv250002r25","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1111\/bjh.16627","article-title":"Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.","volume":"189","author":"Gong","year":"2020","journal-title":"Br J Haematol"},{"issue":"22","key":"jrv250002r26","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"jrv250002r27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.","volume":"37","author":"Senapati","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"jrv250002r28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12185-024-03787-z","article-title":"Outcome of 3q26.2\/MECOM rearrangements in chronic myeloid leukemia.","volume":"120","author":"Akiyama","year":"2024","journal-title":"Int J Hematol"},{"issue":"20","key":"jrv250002r29","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"jrv250002r30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"jrv250002r31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"jrv250002r32","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","article-title":"The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.","volume":"34","author":"Pfirrmann","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"jrv250002r33","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms.","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"jrv250002r34","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ajh.27007","article-title":"Classification of accelerated phase chronic myeloid leukemia in the era of the BCR:ABL1 tyrosine kinase inhibitors: a work in progress.","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"jrv250002r35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.23.01689","article-title":"CML and the WHO: why?","volume":"42","author":"Berman","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv250002r36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"jrv250002r37","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients trial.","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"jrv250002r38","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"jrv250002r39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"jrv250002r40","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1200\/JCO.2019.37.15_suppl.3060","article-title":"Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective?","volume":"37","author":"Corbaux","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"jrv250002r41","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"issue":"12","key":"jrv250002r42","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ajh.25284","article-title":"The \u201cAmerican (cancer) patients first\u201d plan to reduce drug prices\u2014a critical assessment.","volume":"93","author":"Kantarjian","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"jrv250002r43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41375-024-02229-3","article-title":"Are there new relevant therapeutic endpoints in the modern era of the BCR:ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?","volume":"38","author":"Kantarjian","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"jrv250002r44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"jrv250002r45","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41375-021-01173-w","article-title":"Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.","volume":"35","author":"Richter","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"jrv250002r46","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"16","key":"jrv250002r47","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission.","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv250002r48","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE.","volume":"202","author":"Shah","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"jrv250002r49","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"jrv250002r51","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"10","key":"jrv250002r52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results.","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"jrv250002r53","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv250002r54","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"jrv250002r55","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia.","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv250002r56","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones.","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"jrv250002r57","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s41375-023-02053-1","article-title":"What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?","volume":"37","author":"Kantarjian","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"jrv250002r59","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7116","article-title":"Navigating the management of chronic phase cml in the era of generic BCR:ABL1 tyrosine kinase inhibitors.","volume":"22","author":"Haddad","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"jrv250002r60","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1016\/S2352-3026(23)00164-3","article-title":"Revisiting six established practices in the treatment of chronic myeloid leukaemia.","volume":"10","author":"Kantarjian","year":"2023","journal-title":"Lancet Haematol"},{"key":"jrv250002r61","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia\u2014what to look for when treatment-free remission is not an option.","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"13","key":"jrv250002r62","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"12","key":"jrv250002r63","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1200\/JCO.2010.33.9176","article-title":"Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"jrv250002r64","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"4","key":"jrv250002r65","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ajh.26836","article-title":"Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor.","volume":"98","author":"Bidikian","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"jrv250002r66","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"13","key":"jrv250002r67","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"jrv250002r68","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/ajh.26852","article-title":"The outcomes of patients with chronic myeloid leukemia treated with third-line BCR:ABL1 tyrosine kinase inhibitors.","volume":"98","author":"Jabbour","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"jrv250002r69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"3","key":"jrv250002r70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"jrv250002r71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"21","key":"jrv250002r72","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"21","key":"jrv250002r73","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"7","key":"jrv250002r74","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after =1 prior tyrosine kinase inhibitor: 2-year follow-up results.","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"jrv250002r75","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"key":"jrv250002r76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.839915","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: a feasible option also in the real-life: a Campus CML study.","volume":"12","author":"Iurlo","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"jrv250002r77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"jrv250002r78","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ajh.27037","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.","volume":"98","author":"Haddad","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"jrv250002r79","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41409-019-0513-5","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML Registry.","volume":"54","author":"L\u00fcbking","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"jrv250002r80","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.","volume":"92","author":"Oyekunle","year":"2013","journal-title":"Ann Hematol"},{"issue":"2","key":"jrv250002r81","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"2","key":"jrv250002r82","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","article-title":"Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial.","volume":"9","author":"Copland","year":"2022","journal-title":"Lancet Haematol"},{"key":"jrv250002r83","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1182\/blood-2022-170773","article-title":"A phase II study of the combination of decitabine, venetoclax and ponatinib in patients with chronic myeloid leukemia (CML) in myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML).","volume":"140","author":"Senapati","year":"2022","journal-title":"Blood"},{"key":"jrv250002r2","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"Kantarjian","year":"2022","edition":"21st ed"},{"key":"jrv250002r50","author":"Breccia","year":"2024"},{"key":"jrv250002r58","author":"Belohlavkova","year":"2024"},{"key":"jrv250002r3","unstructured":"American Cancer Society. Key statistics for chronic myeloid leukemia. Accessed January 27, 2025. https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/about\/statistics.html"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2831659\/jama_jabbour_2025_rv_250002_1746123749.917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T11:01:27Z","timestamp":1747134087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2831659"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":83,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.0220","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}